| Primary |
| Infection |
14.6% |
| Pyrexia |
12.4% |
| Product Used For Unknown Indication |
8.0% |
| Tuberculosis |
7.3% |
| Febrile Neutropenia |
6.6% |
| Parkinson's Disease |
5.1% |
| Psychotic Disorder |
5.1% |
| Abscess |
4.4% |
| Neutropenia |
4.4% |
| B Precursor Type Acute Leukaemia |
3.6% |
| Enterococcal Infection |
3.6% |
| Lung Disorder |
3.6% |
| Lower Respiratory Tract Infection |
2.9% |
| Osteomyelitis |
2.9% |
| Pneumonia |
2.9% |
| Productive Cough |
2.9% |
| Sepsis |
2.9% |
| Abdominal Sepsis |
2.2% |
| Acute Myeloid Leukaemia |
2.2% |
| Acute Myeloid Leukaemia Recurrent |
2.2% |
|
| Tubulointerstitial Nephritis |
12.2% |
| Renal Failure Acute |
10.2% |
| Vomiting |
10.2% |
| Urticaria |
6.1% |
| Death |
4.1% |
| Drug Eruption |
4.1% |
| Hypersensitivity Vasculitis |
4.1% |
| Nephropathy Toxic |
4.1% |
| Pruritus |
4.1% |
| Pyrexia |
4.1% |
| Rash Maculo-papular |
4.1% |
| Rash Pruritic |
4.1% |
| Renal Impairment |
4.1% |
| Sepsis |
4.1% |
| Thrombocytopenia |
4.1% |
| Toxic Epidermal Necrolysis |
4.1% |
| Toxic Skin Eruption |
4.1% |
| Wrong Technique In Drug Usage Process |
4.1% |
| Anaphylactic Reaction |
2.0% |
| Angioedema |
2.0% |
|
| Secondary |
| Product Used For Unknown Indication |
37.0% |
| Infection |
8.3% |
| Bronchopneumonia |
7.0% |
| Pneumonia |
6.8% |
| Pneumonia Aspiration |
4.6% |
| Bacterial Infection |
4.4% |
| Staphylococcal Infection |
4.4% |
| Retroperitoneal Abscess |
3.9% |
| Lower Respiratory Tract Infection |
3.7% |
| Abscess |
3.5% |
| Cholecystitis Acute |
2.2% |
| Cystitis |
2.0% |
| Epilepsy |
2.0% |
| Pyrexia |
1.8% |
| Enterococcal Infection |
1.5% |
| Pseudomonas Infection |
1.5% |
| Sepsis |
1.5% |
| Atrial Flutter |
1.3% |
| Clostridial Infection |
1.3% |
| Drug Therapy |
1.3% |
|
| White Blood Cell Count Increased |
9.3% |
| Linear Iga Disease |
7.4% |
| Neutropenia |
7.4% |
| Renal Failure Acute |
7.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
5.6% |
| Hypertriglyceridaemia |
5.6% |
| Loss Of Consciousness |
5.6% |
| Respiratory Arrest |
5.6% |
| Septic Shock |
5.6% |
| Agranulocytosis |
3.7% |
| Atrioventricular Block Complete |
3.7% |
| Clostridial Infection |
3.7% |
| Diarrhoea |
3.7% |
| Drug Ineffective |
3.7% |
| Lung Disorder |
3.7% |
| Pathogen Resistance |
3.7% |
| Pneumonia Haemophilus |
3.7% |
| Swelling |
3.7% |
| Thrombocytopenia |
3.7% |
| Tubulointerstitial Nephritis |
3.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.9% |
| Drug Use For Unknown Indication |
15.0% |
| Prophylaxis |
8.5% |
| Sarcoma Metastatic |
7.5% |
| Pneumonia |
6.0% |
| Pain |
4.7% |
| Infection |
4.0% |
| Bronchitis |
3.0% |
| Lung Infection |
3.0% |
| Diabetes Mellitus |
2.7% |
| Graft Versus Host Disease |
2.7% |
| Nausea |
2.7% |
| Premedication |
2.7% |
| Antibiotic Prophylaxis |
2.5% |
| Immunosuppression |
2.5% |
| Rhabdomyosarcoma |
2.5% |
| B Precursor Type Acute Leukaemia |
2.2% |
| Hypertension |
2.2% |
| Insomnia |
2.2% |
| Type 2 Diabetes Mellitus |
2.2% |
|
| Mucosal Inflammation |
8.2% |
| Renal Failure Acute |
8.2% |
| Renal Tubular Necrosis |
8.2% |
| Drug Ineffective |
6.6% |
| Sepsis |
6.6% |
| Systemic Candida |
6.6% |
| Torsade De Pointes |
6.6% |
| Arthralgia |
4.9% |
| Death |
4.9% |
| Septic Shock |
4.9% |
| Thrombocytopenia |
4.9% |
| Cholestasis |
3.3% |
| Eosinophilic Pneumonia |
3.3% |
| Malaise |
3.3% |
| Multi-organ Failure |
3.3% |
| Neutropenia |
3.3% |
| Pneumothorax |
3.3% |
| Red Man Syndrome |
3.3% |
| Renal Failure |
3.3% |
| Respiratory Failure |
3.3% |
|
| Interacting |
| Infection |
29.4% |
| Atrial Flutter |
11.8% |
| Bacteraemia |
11.8% |
| Pneumonia |
11.8% |
| Pulmonary Embolism |
11.8% |
| Pain |
5.9% |
| Pain In Extremity |
5.9% |
| Product Used For Unknown Indication |
5.9% |
| Psoriatic Arthropathy |
5.9% |
|
| International Normalised Ratio Increased |
25.0% |
| Overdose |
25.0% |
| Rash Erythematous |
25.0% |
| Retroperitoneal Haematoma |
25.0% |
|
